Table 2.
Baseline patient characteristics and cMRI parameters
| Brown 2020 | Lee 2021 | Santos‐Gallego 2021 | Singh 2020 | Verma 2019 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SGLT2i | Placebo | SGLT2i | Placebo | SGLT2i | Placebo | SGLT2i | Placebo | SGLT2i | Placebo | |
| Baseline characteristics | ||||||||||
| Age (years) | 64.25 ± 7.01 | 66.74 ± 6.62 | 68.2 ± 11.7 | 69.2 ± 10.6 | 64.2 ± 10.9 | 59.9 ± 13.1 | 66.9 ± 7.0 | 67.4 ± 6.8 | 64 (57, 69) b | 64 (56, 72) b |
| Male sex | 20 (62.5) | 18 (52.9) | 34 (65.4) | 43 (81.1) | 27 (64) | 27 (64) | 18 (64.3) | 19 (67.9) | 44 (90) | 46 (96) |
| BMI (kg/m2) | 32.30 ± 4.66 | 32.59 ± 4.22 | 30.9 ± 5.9 | 30.4 ± 5.1 | 29.3 ± 6 | 30 ± 6 | 33.0 ± 5.5 | 32 ± 5.2 | 27.7 ± 4.7 | 27.4 ± 5.4 |
| HbA1c | 61.75 ± 11.19 mmol/mol | 60.18 ± 10.15 mmol/mol | 7.5 ± 1.6% | 7.0 ± 1.4% | 5.8 ± 0.3% | 5.8 ± 0.5% | 63.0 ± 17.8 mmol/mol | 58.6 ± 16.4 mmol/mol | 7.9 ± 0.8% | 8.0 ± 0.9% |
| SBP (mmHg) | 130.41 ± 9.62 | 127.67 ± 10.65 | 125.8 ± 18.2 | 130.3 ± 21.6 | NR | NR | 135 ± 15.4 | 132.8 ± 18.8 | 139 ± 15 | 138 ± 15 |
| NYHA class of HF | ||||||||||
| Class I | NR | NR | 0 (0.0) | 0 (0.0) | NR | NR | 12 (42.9) | 13 (46.4) | NR | NR |
| Class II | NR | NR | 37 (71.2) | 44 (83.0) | NR | NR | 13 (46.4) | 11 (39.3) | NR | NR |
| Class III | NR | NR | 15 (28.8) | 9 (17.0) | NR | NR | 3 (10.7) | 4 (14.3) | NR | NR |
| Class IV | NR | NR | 0 (0.0) | 0 (0.0) | NR | NR | 0 (0.0) | 0 (0.0) | NR | NR |
| Baseline CMR parameters | ||||||||||
| Baseline LVM (g) | 126.47 ± 20.54 | 121.61 ± 24.20 | 121.2 ± 36.5 | 131.9 ± 44.9 | 135.2 ± 45.2 | 131.8 ± 54.4 | NR | NR | 116.5 ± 26.3 | 120.9 ± 33.0 |
| Baseline LVMi (g/m2) a | 60.92 ± 7.76 | 59.04 ± 8.73 | 61.2 ± 16.1 | 65.4 ± 19.6 | 67.9 ± 17.8 | 65.9 ± 19.8 | 69.5 ± 16.3 | 73.7 ± 19.3 | 59.3 ± 10.9 | 62.2 ± 12.8 |
| Baseline LVESV (mL) | 37.17 ± 9.92 | 33.63 ± 11.13 | 157.5 ± 68.1 | 152.9 ± 58.4 | 143.6 ± 66.3 | 135.1 ± 54.8 | 99.2 ± 40.7 | 106.4 ± 59.6 | 53.0 ± 20.8 | 62.5 ± 26.0 |
| Baseline LVEDV (mL) | 127.63 ± 22.54 | 120.66 ± 25.29 | 224.8 ± 72.2 | 222.7 ± 60.1 | 219.8 ± 75.8 | 210.4 ± 68.9 | 172.4 ± 47.7 | 188.3 ± 72.4 | 124.1 ± 33.0 | 138.4 ± 39.1 |
| Baseline LVEF (%) | 71.31 ± 5.42 | 72.54 ± 6.27 | 31.7 ± 9.9 | 33.0 ± 9.5 | 36.2 ± 8.2 | 36.5 ± 8 | 44.5 ± 12.4 | 46.5 ± 11.7 | 58.0 ± 7.5 | 55.5 ± 8.7 |
Data are mean ± SD, n (%) except where otherwise specified.
BMI, body mass index; cMRI, cardiac magnetic resonance imaging; HbA1c, haemoglobin A1c; HF, heart failure; LVEDV, left ventricular end diastolic volume; LVEF, left ventricular ejection fraction; LVM, left ventricular mass; LVMi, indexed left ventricular mass; LVESV, left ventricular end systolic volume; NYHA, New York Heart Association; SBP, systolic blood pressure; SGLT2i, sodium‐glucose cotransporter‐2 inhibitors.
a
Indexed to body surface area.
b
Age provided as median (IQR) for this study.